vTv Therapeutics Inc.
VTVT
$22.74
$7.8953.13%
| Weiss Ratings | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.11 | |||
| Price History | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 47.75% | |||
| 30-Day Total Return | 44.66% | |||
| 60-Day Total Return | 46.99% | |||
| 90-Day Total Return | 62.43% | |||
| Year to Date Total Return | 67.55% | |||
| 1-Year Total Return | 13.02% | |||
| 2-Year Total Return | -25.20% | |||
| 3-Year Total Return | -15.35% | |||
| 5-Year Total Return | -65.12% | |||
| 52-Week High % Change | -26.62% | |||
| 52-Week Low % Change | 87.62% | |||
| Price | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $30.99 | |||
| 52-Week Low Price | $12.12 | |||
| 52-Week Low Price (Date) | Jul 29, 2024 | |||
| 52-Week High Price (Date) | Mar 21, 2024 | |||
| Valuation | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 59.40M | |||
| Enterprise Value | 20.86M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -7.63 | |||
| Earnings Per Share Growth | -26.47% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 59.40 | |||
| Price/Book (Q) | 3.96 | |||
| Enterprise Value/Revenue (TTM) | 20.86 | |||
| Price | $22.74 | |||
| Enterprise Value/EBITDA (TTM) | -0.87 | |||
| Enterprise Value/EBIT | -0.87 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 2.61M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 336 841 0300 | |||
| Address | 3980 Premier Drive High Point, NC 27265 | |||
| Website | vtvtherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2015 | |||
| Profitability | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -2,399.50% | |||
| Profit Margin | -1,830.60% | |||
| Management Effectiveness | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -51.64% | |||
| Return on Equity | -- | |||
| Income Statement | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.00M | |||
| Total Revenue (TTM) | 1.00M | |||
| Revenue Per Share | $0.38 | |||
| Gross Profit (TTM) | -7.23M | |||
| EBITDA (TTM) | -23.91M | |||
| EBIT (TTM) | -24.00M | |||
| Net Income (TTM) | -18.31M | |||
| Net Income Avl. to Common (TTM) | -18.31M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 31.62% | |||
| EPS Diluted (TTM) | -7.63 | |||
| EPS Diluted Growth (Q YOY) | 42.63% | |||
| Balance Sheet | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 41.66M | |||
| Cash Per Share (Q) | $15.95 | |||
| Total Current Assets (Q) | 42.96M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 17.91M | |||
| Current Ratio (Q) | 6.687 | |||
| Book Value Per Share (Q) | $5.75 | |||
| Total Assets (Q) | 43.16M | |||
| Total Current Liabilities (Q) | 6.42M | |||
| Total Debt (Q) | 213.00K | |||
| Total Liabilities (Q) | 25.25M | |||
| Total Common Equity (Q) | 15.01M | |||
| Cash Flow | VTVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 4.40M | |||
| Cash from Financing (TTM) | 52.33M | |||
| Net Change in Cash (TTM) | 33.33M | |||
| Levered Free Cash Flow (TTM) | -15.40M | |||
| Cash from Operations (TTM) | -23.40M | |||
